Abstract
The resistance to growth inhibition commonly observed in a variety of TGFb disabled human cancers, the potential role of TGFb in the exacerbation of malignancy and the effects of TGFb in suppressing the immune system, all emphasize the importance of pathways mediated by this polypeptide to the neoplastic process. Early investigations to understand the molecular basis of cancer due to defects in TGFb signaling were concentrated on examining the abundance of biologically active TGFb and its binding to TGFb receptors. However, major breakthroughs in understanding the molecular basis of the TGFb mediated effects in cancer came from genetic evidence for inactivation of the various players in its signaling cascade. The vast majority of current evidence is derived from the identification of mutations causing structural defects in TGFb receptors and Smad genes, the downstream effectors of the TGFb signaling pathway that have emerged from the analysis of human cancers. The involvement of Smads at the receptor level upon activation by a TGFb bound receptor, their participation in signal transmission to the nucleus and their direct roles in the regulation of target genes have made the various Smad genes critical targets for inactivation of TGFb signaling in cancer. To date, eight human homologues of the Smad genes have been identified and are classified into three distinct classes based on their structure and function. In this review, we discuss TGFb signaling via the Smads and the known and predicted points at which TGFb signaling could become altered in human cancer.
Current Genomics
Title: TGFb and its Smad Connection to Cancer
Volume: 3 Issue: 5
Author(s): S. Thiagalingam, K- h. Cheng, R. L. Foy, H. J. Lee, D. Chinnappan and J. F. Ponte
Affiliation:
Abstract: The resistance to growth inhibition commonly observed in a variety of TGFb disabled human cancers, the potential role of TGFb in the exacerbation of malignancy and the effects of TGFb in suppressing the immune system, all emphasize the importance of pathways mediated by this polypeptide to the neoplastic process. Early investigations to understand the molecular basis of cancer due to defects in TGFb signaling were concentrated on examining the abundance of biologically active TGFb and its binding to TGFb receptors. However, major breakthroughs in understanding the molecular basis of the TGFb mediated effects in cancer came from genetic evidence for inactivation of the various players in its signaling cascade. The vast majority of current evidence is derived from the identification of mutations causing structural defects in TGFb receptors and Smad genes, the downstream effectors of the TGFb signaling pathway that have emerged from the analysis of human cancers. The involvement of Smads at the receptor level upon activation by a TGFb bound receptor, their participation in signal transmission to the nucleus and their direct roles in the regulation of target genes have made the various Smad genes critical targets for inactivation of TGFb signaling in cancer. To date, eight human homologues of the Smad genes have been identified and are classified into three distinct classes based on their structure and function. In this review, we discuss TGFb signaling via the Smads and the known and predicted points at which TGFb signaling could become altered in human cancer.
Export Options
About this article
Cite this article as:
Thiagalingam S., Cheng h. K-, Foy L. R., Lee J. H., Chinnappan D. and Ponte F. J., TGFb and its Smad Connection to Cancer, Current Genomics 2002; 3 (5) . https://dx.doi.org/10.2174/1389202023350291
DOI https://dx.doi.org/10.2174/1389202023350291 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Expression and Function of Anti-Inflammatory Interleukins: The Other Side of the Vascular Response to Injury
Current Vascular Pharmacology Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Current Respiratory Medicine Reviews From Alpha to Omega with Aβ: Targeting the Multiple Molecular Appearances of the Pathogenic Peptide in Alzheimers Disease
Current Medicinal Chemistry Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
Current Drug Metabolism Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Pharmacological Approaches of Binge Drinking
Current Pharmaceutical Design Recent Patents for the Treatment of Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Impulse Control Disorders in Parkinson’s Disease: A Review
Current Psychiatry Reviews Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Antiangiogenesis in Myelodysplastic Syndrome
Current Cancer Drug Targets Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Impact of Fc Receptors on the Development of Autoimmune Diseases
Current Pharmaceutical Design Recent Developments of Flavonoids with Various Activities
Current Topics in Medicinal Chemistry